Today Syncona announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35 million commitment in a Series A financing of which [...]
Portico Ventures Programme spinout Odin Vision, which is using space technology to improve the early detection and diagnosis of bowel cancer, has secured £1 mil [...]
Download the UCLB Annual Review as a PDF. [...]
Conference Call and Webcast to Be Held Tuesday, April 2, 2019 at 8:00 am ET / 1:00 pm BST UCLB spinout, Autolus Therapeutics, a clinical-stage biopharmaceutical [...]
UCLB, the wholly owned subsidiary technology commercialisation company of UCL, has appointed Dr Anne Lane as its new Managing Director. As part of UCL Innovatio [...]
London, UK, December 17th, 2018. LifeArc, a leading UK medical research charity, is delighted to launch a new Technology Transfer Fellowship programme in partn [...]
Medical software developed at UCL that overlays tumour information from MRI scans onto ultrasound images can help guide surgeons conducting biopsies and improve [...]
The government has published the second Life Sciences Sector Deal, which outlines public and private sector investments into the sector. Investments into three [...]
A single infusion of FLT180a resulted in sustained mean Factor IX activity of 45%, with no toxicity or adverse effects, and eliminated need for patient infusion [...]
UCLTF has invested in a series A round for immuno-oncology company IGEM Therapeutics. The £5million funding round also included investment from Alsa Holdings an [...]
